Live Breaking News & Updates on Master Trial

Stay updated with breaking news from Master trial. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Optimizing Bispecific Use in Multiple Myeloma Treatment

A key opinion leader explores the integration of bispecifics into MM therapy regimens. ....

Conference Perspectives , Multiple Myeloma , Bispecific Use , Master Trial , Durable Response , Four Drug Combination ,

ASH 2023: PERSEUS Trial Overview

Rafael Fonseca, MD, discusses findings from the PERSEUS trial presented in December at ASH 2023. ....

Conference Perspectives , Multiple Myeloma , American Society Of Hematology , Newly Diagnosed Multiple Myeloma , Triplet Therapy , Quadruplet Therapy , Perseus Trial , Transplant Eligible , Master Trial , Durable Response , Four Drug Combination ,

Treatment Duration in Patients With Newly Diagnosed Multiple Myeloma

A panel of experts reflects on treatment duration and its role in optimizing management of patients with newly diagnosed multiple myeloma. ....

Evolving Treatment Paradigm , Multiple Myeloma , Recent Updates , Patients With Newly Diagnosed Multiple , Myeloma Cancer , Newly Diagnosed Multiple Myeloma , Griffin Trial , Griffin Study , Master Trial , Mcmaster Study , Duration Of Therapy , Duration Of Treatment , Discontinuing Therapy , Stopping Therapy , Fixed Duration Therapy , Minimal Residual Disease , Asco 2023 , Asco Annual Meeting ,

Dr Callander on Ongoing and Future Clinical Trials in Multiple Myeloma at Carbone Cancer Center

Natalie S. Callander, MD, discusses several ongoing and planned clinical trials evaluating the use of novel therapeutic regimens in multiple myeloma. ....

University Of Wisconsin , United States , Natalies Callander , Division Of Hematology , Carbone Cancer Center , University Of Wisconsin School Medicine , Department Of Medicine , Public Health , Medical Oncology , Palliative Care , Wisconsin School , University Of Wisconsin School Medicine And Public Health , University Of Wisconsin Carbone Cancer Center , Master Trial , Patients With Multiple Myeloma ,

Dr Callander on Investigational Maintenance Regimens in Multiple Myeloma

Natalie S. Callander, MD, discusses the significance of the phase 3 ATLAS, phase 2 FORTE, and phase 2 MASTER trials in patients with multiple myeloma. ....

University Of Wisconsin , United States , Public Health , Division Of Hematology , University Of Wisconsin School Medicine , Department Of Medicine , Medical Oncology , Palliative Care , Wisconsin School , Natalies Callander , University Of Wisconsin School Medicine And Public Health , University Of Wisconsin Carbone Cancer Center , Atlas Trial , Forte Trial , Master Trial , Patients With Multiple Myeloma ,